CONVIVO®
confocal
ex vivo
fluorescein
glioblastoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
09
2020
accepted:
19
11
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Confocal laser endomicroscopy (CLE) allowing intraoperative near real-time high-resolution cellular visualization is a promising method in neurosurgery. We prospectively tested the accuracy of a new-designed miniatured CLE (CONVIVO® system) in giving an intraoperative first-diagnosis during glioblastoma removal. Between January and May 2018, 15 patients with newly diagnosed glioblastoma underwent fluorescein-guided surgery. Two biopsies from both tumor central core and margins were harvested, dividing each sample into two specimens. Biopsies were firstly intraoperatively Blindly comparing CONVIVO® and frozen sections images we obtained a high rate of concordance in both providing a correct diagnosis and categorizing patterns at tumor central core (80 and 93.3%, respectively) and at tumor margins (80% for both objectives). Comparing CONVIVO® and permanent sections, concordance resulted similar at central core (total/partial concordance in 80 and 86.7% for diagnosis and morphological categorization, respectively) and lower at tumor margins (66.6% for both categories). Time from fluorescein injection and time from biopsy sampling to CONVIVO® scanning was 134 ± 31 min (122-214 min) and 9.23 min (1-17min), respectively. Mean time needed for CONVIVO® images interpretation was 5.74 min (1-7 min). The high rate of diagnostic/morphological consistency found between CONVIVO® and frozen section analyses suggests the possibility to use CLE as a complementary tool for intraoperative diagnosis of
Sections du résumé
BACKGROUND
BACKGROUND
Confocal laser endomicroscopy (CLE) allowing intraoperative near real-time high-resolution cellular visualization is a promising method in neurosurgery. We prospectively tested the accuracy of a new-designed miniatured CLE (CONVIVO® system) in giving an intraoperative first-diagnosis during glioblastoma removal.
METHODS
METHODS
Between January and May 2018, 15 patients with newly diagnosed glioblastoma underwent fluorescein-guided surgery. Two biopsies from both tumor central core and margins were harvested, dividing each sample into two specimens. Biopsies were firstly intraoperatively
RESULTS
RESULTS
Blindly comparing CONVIVO® and frozen sections images we obtained a high rate of concordance in both providing a correct diagnosis and categorizing patterns at tumor central core (80 and 93.3%, respectively) and at tumor margins (80% for both objectives). Comparing CONVIVO® and permanent sections, concordance resulted similar at central core (total/partial concordance in 80 and 86.7% for diagnosis and morphological categorization, respectively) and lower at tumor margins (66.6% for both categories). Time from fluorescein injection and time from biopsy sampling to CONVIVO® scanning was 134 ± 31 min (122-214 min) and 9.23 min (1-17min), respectively. Mean time needed for CONVIVO® images interpretation was 5.74 min (1-7 min).
CONCLUSIONS
CONCLUSIONS
The high rate of diagnostic/morphological consistency found between CONVIVO® and frozen section analyses suggests the possibility to use CLE as a complementary tool for intraoperative diagnosis of
Identifiants
pubmed: 33425764
doi: 10.3389/fonc.2020.606574
pmc: PMC7787149
doi:
Types de publication
Journal Article
Langues
eng
Pagination
606574Informations de copyright
Copyright © 2020 Acerbi, Pollo, De Laurentis, Restelli, Falco, Vetrano, Broggi, Schiariti, Tramacere, Ferroli and DiMeco.
Déclaration de conflit d'intérêts
FA received fees from Carl Zeiss Meditec for lectures at International Congresses. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BJOG. 2009 Nov;116(12):1663-70
pubmed: 19781048
World Neurosurg. 2018 Jul;115:e337-e348
pubmed: 29673821
Front Oncol. 2019 Jul 03;9:554
pubmed: 31334106
Gastrointest Endosc. 2009 Oct;70(4):645-54
pubmed: 19559419
Front Surg. 2016 Oct 17;3:55
pubmed: 27800481
Surg Neurol Int. 2014 Apr 28;5:60
pubmed: 24872922
Neurosurg Focus. 2014 Feb;36(2):E16
pubmed: 24484254
Minim Invasive Surg. 2013;2013:851819
pubmed: 23984062
PLoS One. 2012;7(7):e41760
pubmed: 22911853
Neurosurgery. 2010 Feb;66(2):410-7; discussion 417-8
pubmed: 20087141
Brain Pathol. 2013 Jan;23(1):73-81
pubmed: 22882328
Front Oncol. 2019 Jul 18;9:583
pubmed: 31380264
Surg Neurol Int. 2016 Dec 12;7(Suppl 40):S995-S1003
pubmed: 28144472
J Neurosurg Sci. 2018 Dec;62(6):704-717
pubmed: 30160080
Arch Pathol Lab Med. 2007 Oct;131(10):1532-40
pubmed: 17922589
J Oral Maxillofac Pathol. 2014 Sep;18(Suppl 1):S111-6
pubmed: 25364159
J Neurosurg. 2015 Jun;122(6):1360-9
pubmed: 25839919
Neurosurg Focus. 2016 Mar;40(3):E11
pubmed: 26926051
Brain Pathol. 2013 Jul;23(4):371-7
pubmed: 23356716
World Neurosurg. 2017 Apr;100:180-185
pubmed: 28069420
World Neurosurg. 2018 Jul;115:110-127
pubmed: 29653276
J Clin Med. 2020 Sep 29;9(10):
pubmed: 33003336
Cancer Manag Res. 2018 Aug 30;10:3109-3123
pubmed: 30214304
Acta Neurochir (Wien). 2015 Sep;157(8):1377-8
pubmed: 26021579
Clin Cancer Res. 2018 Jan 1;24(1):52-61
pubmed: 29018053
Neurosurgery. 2016 Oct;79(4):604-12
pubmed: 27643918
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Brain Tumor Res Treat. 2015 Apr;3(1):8-23
pubmed: 25977902
J Neurosurg. 2012 Apr;116(4):854-60
pubmed: 22283191
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009